Current stock page

Financial Data

TYRA Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

TYRATyra Biosciences, Inc.

Healthcare / Biotechnology

Relative Leader / Watch

Strong Relative Position

BearishEdge 8/10
$20.03+$0.26 (+1.32%)

Latest quote

  • Momentum
    27
  • Value
    —
  • Quality
    75
  • Risk resilience
    45
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$0$0$0$0$0$0$0$0
Gross Profit-$130K$0-$138K$0$0$0$0$0
Operating Income-$54.89M-$49M-$42M-$36.52M-$32.94M-$31.45M-$31.85M-$29.74M
Net Income-$51.12M-$45.56M-$39.31M-$33.83M-$29.87M-$28.1M-$28.15M-$25.57M
EPS-$0.74-$0.69-$0.64-$0.57-$0.5-$0.47-$0.47-$0.43
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow-$32.21M-$31.08M-$32.57M-$23.62M-$22.38M-$23.68M-$25.46M-$19.59M
Capital Expenditure-$90K-$66K-$88K-$57K-$39K-$31K-$14K-$6K
Free Cash Flow-$32.3M-$31.14M-$32.66M-$23.68M-$22.42M-$23.71M-$25.47M-$19.6M
Net Cash Provided By Operating Activities-$32.21M-$31.08M-$32.57M-$23.62M-$22.38M-$23.68M-$25.46M-$19.59M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$727.53M$383.36M$412.04M$282.61M$301.85M$321.5M$343.48M$363.56M
Total Debt$5.46M$5.58M$5.7M$5.81M$5.92M$6.02M$6.12M$6.22M
Cash And Cash Equivalents$456.02M$73.84M$84.96M$77.39M$61.95M$98.49M$100.72M$91.97M
Total Liabilities$34.68M$29.7M$24.47M$23.43M$21.34M$19.35M$19.94M$20.41M
Total Stockholders Equity$692.84M$353.66M$387.58M$259.18M$280.51M$302.15M$323.53M$343.15M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio2.096.075.777.483.152.111.851.66
P/S ratio————————
Debt To Equity0.010.020.010.020.020.020.020.02
Free Cash Flow Yield-8.27%-5.12%-4.59%-4.92%-10.31%-13.61%-12.34%-12.39%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio2.096.075.777.483.152.111.851.66
P/S ratio————————
Return On Equity-24.51%-42.01%-33.83%-46.28%-39.81%-35.03%-29.81%-25.20%
Debt To Equity0.010.020.010.020.020.020.020.02

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe-7.59x
Pb2x
EPS Growth Yoy-48.00%
Gross Margin0.00%
Operating Margin0.00%
ROE-40.12%
ROIC-26.12%
Debt To Equity0.01
FCF Yield-8.67%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$20.03
Volume375,086
RSI (14)42.76
MACD-0.23
MACD signal-0.21
MACD histogram-0.02
ADX (14)12.07
SMA (50)$21.75
SMA (200)$29.41
ATR (14)$1.16
Historical volatility (annualized)51.76%
Volume (20-day average)627,688

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score45/100
Beta0.53
Annual volatility67.91%
Max Drawdown-53.24%
Sharpe Ratio0.65
VaR (95%, 1-day)-5.27%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

TYRA Financial Data FAQ

What is Tyra Biosciences, Inc.'s revenue?

Tyra Biosciences, Inc.'s revenue is one of the core financial data points for TYRA. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Tyra Biosciences, Inc.'s revenue growing?

Revenue growth shows whether Tyra Biosciences, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is TYRA's EPS?

TYRA's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Tyra Biosciences, Inc.'s net income?

Tyra Biosciences, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Tyra Biosciences, Inc. generate?

Free cash flow shows how much cash Tyra Biosciences, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Tyra Biosciences, Inc. have?

Cash and debt help frame TYRA's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.